骨改良药物在乳腺癌骨转移治疗中的应用进展  

Progression of bone-modifying agents for the treatment of bone metastases in breast cancer

作　　者：王如良[1] 江泽飞[1] 

机构地区：[1]解放军军事医学科学院附属医院乳腺肿瘤科,北京100071

出　　处：《临床肿瘤学杂志》2016年第5期458-461,共4页Chinese Clinical Oncology

摘　　要：骨改良药物包括在临床上应用的双膦酸盐及2010年FDA批准上市的新药地诺单抗,是目前治疗恶性肿瘤骨转移、高钙血症及骨质疏松症的主要药物。该类药物在临床上应用广泛,种类较多,近年来在药物的应用时机、用法及毒副反应方面有一定进展和争议。本文就骨改良药物在乳腺癌骨转移治疗中的临床应用进行探讨。The bone-modifying agents （BMAs）, including the bisphosphonates （BPs） and the monoclonal antibody denosum-ab which was approved by FDA in 2010, have a long established role in the management of osteoporosis, hypercalcemia of malignancy and bone metastases from malignant tumors. In recent years, the use of the agents such as the medication time, the usage and side effects has certain progress and controversy. In this review we summarize the development of bone-modifying agents for the treatment of bone metastases in breast cancer.

关 键 词：乳腺癌 骨转移 骨改良药物 

分 类 号：R737.9[医药卫生—肿瘤]